Wound Care Biologics Global Market Report 2024

The wound care biologics market has grown strongly in recent years. It will grow from $1.76 billion in 2023 to $1.93 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The expansion observed in the historical period can be credited to the presence of clinical evidence and studies, the development of regulatory frameworks, the evolution of the wound care market, the existence of limited treatment options, and concerted research and development efforts.

The wound care biologics market is expected to see strong growth in the next few years. It will grow to $2.71 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated expansion in the forecast period can be ascribed to a heightened focus on personalized medicine, an increase in healthcare expenditure, the adoption of value-based healthcare models, a growing demand for advanced therapies, and supportive regulatory measures and approvals. Major trends expected in the forecast period encompass an emphasis on regenerative medicine, the utilization of bioengineered skin substitutes, the introduction of innovative delivery systems, a rise in chronic wound management, and a commitment to patient-centric care.

The anticipated growth of the wound care biologics market in the near future is expected to be propelled by the high prevalence of diabetes. Diabetes, characterized by elevated blood glucose levels, leads to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. Wound care biologics play a crucial role in preventing volatile water loss, heat loss, protein and electrolyte loss, and contamination associated with diabetes. They also facilitate autolytic debridement and generate a granular wound layer. The market is driven by the substantial prevalence of diabetes, as highlighted in the IDF Diabetes Atlas Tenth Edition 2021 report, which estimated 537 million individuals (20-79 years old) with diabetes in 2021. The projections indicate a rise to 643 million by 2030 and 783 million by 2045, underscoring the impact of diabetes on the wound care biologics market.

The growth of the wound care biologics market is expected to be fueled by the increasing number of surgical procedures. Surgical procedures involve medical interventions that include incisions or the use of instruments to address various medical conditions. Wound care biologics, comprising living cells, growth factors, or other biological materials, contribute to the natural healing process. The surge in surgical procedures has heightened interest in advanced wound care solutions, aiming to expedite the healing of surgical wounds, minimize complications, and improve overall patient outcomes. For example, the Czech Republic witnessed an 8.4% increase in cataract surgical procedures, totaling 142,670 procedures in 2022 compared to 131,612 in 2021, according to the Organization for Economic Co-operation and Development. This surge in surgical procedures serves as a driving force for the growth of the wound care biologics market.

Product innovation stands out as a prominent trend gaining traction in the consumer and wound care biologics market. Leading companies in the wound care biologics sector are strategically focusing on the development of innovative products infused with advanced technologies to bolster their market positions. For instance, in April 2021, Kerecis, a US-based company specializing in treating wounds, burns, and complex acute and chronic wounds, introduced the Kerecis Omega3 GraftGuide. This fish skin product, approved by the FDA under the 510(k) regulatory procedure, addresses the challenges associated with burn healing. It enhances autograft take, reduces the necessity for autograft harvesting, and serves as an alternative to autografting.

Skin graft development is a major focus for key companies in the wound care biologics market, aiming to gain a competitive edge. Skin grafting involves a surgical procedure where healthy skin is transplanted from one body area (donor site) to another area that has lost its protective covering due to injury, surgery, burns, or other traumatic conditions. For instance, in July 2022, Tides Medical, a US-based biotechnology company, launched Artacent AC, a tri-layer skin graft designed for treating complex or challenging wounds. With a three-layer structure (amnion-chorion-amnion), it surpasses traditional dual-layer products, being three times stronger and two times thicker. Artacent AC is developed to enhance handling and application to wound sites, offering clinicians an improved solution for complex patient wounds in various medical conditions such as diabetic foot ulcers, chronic wounds, burns, Mohs surgery, and other surgical applications. The product boasts a longer shelf life at room temperature, eliminating the need for refrigeration, and can be placed on either side facing the wound.

In December 2021, Essity AB, a Sweden-based hygiene and health company specializing in one-use products such as compression therapy, orthopedics, and wound care, acquired Hydrofera for $116 million. This strategic acquisition aligns with Essity's goal of expansion through acquisitions in the Medical Solutions sector. Hydrofera, a US-based company, offers antibacterial wound dressings and an advanced line of wound care products.

Major companies operating in the wound care biologics market report are Integra Lifesciences Corporation, Organogenesis Inc., Smith and Nephew plc, Wright Medical Group NV, MiMedx Group Inc., Kerecis AG, Amnio Technology LLC, Anika Therapeutics Inc., ACell Inc., Derma Sciences Inc., Soluble Systems Pvt. Ltd., Medline Industries LP, Solsys Medical LLC, Zimmer Biomet Holdings Inc., MLM Biologics Inc., Tissue Genesis LLC, Stryker Corporation, Marine Polymer Technologies Inc., Bioventus Inc., Mölnlycke Health Care AB, Lynch Biologics LLC, Skye Biologics Holdings LLC, Osiris Therapeutics Inc., Vericel Corporation, TissueTech Inc., PolarityTE Inc., Avita Medical Limited, Celularity Inc., Human Regenerative Technologies LLC, PolyRemedy Inc.

North America was the largest region in the wound care biologics market in 2023. Asia-pacific is expected to be the fastest-growing region in the global wound care biologics market report during the forecast period. The regions covered in the wound care biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the wound care biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products within the field of wound care biologics include biologic skin substitutes and topical agents. Biologic skin substitutes play a crucial role in wound healing and have proven to be highly beneficial within the medical industry. Also known as tissue-engineered products or artificial skin, biologic skin substitutes are biological substances that facilitate wound healing by promoting the generation of new tissues. Wound care biologics are commonly utilized to treat various types of wounds, including ulcers, surgical wounds, traumatic wounds, and burns. The end users of these biologics include hospitals, Ambulatory Surgical Centers (ASCs), burn centers, and wound clinics.

The wound care biologics software market research report provides wound care biologics software market statistics, including wound care biologics software industry global market size, regional shares, competitors with a wound care biologics software market share, detailed wound care biologics software market segments, market trends and opportunities, and any further data you may need to thrive in the wound care biologics software industry. This wound care biologics software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The wound care biologics market consists of revenues earned by entities by providing wound care services such as surgical and traumatic wounds, burns chronic wounds and acute Wounds. The market value includes the value of related goods sold by the service provider or included within the service offering. The wound care biologics market also includes sales of surgical equipment's, medical tape, sponges, cotton pads which are used in providing wound care biologics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.